公开(公告)号：EP2373690A2

公开(公告)日：2011-10-12

申请号：EP09799402.4

申请日：2009-12-08

申请人： Compugen Ltd.

发明人： LEVINE, Zurit ,  ROSENBERG, Avi Yeshah ,  ROTMAN, Galit ,  TOPORIK, Amir ,  KINAR, Yaron ,  NEMZAR, Sergey ,  COHEN-DAYAG, Anat ,  WALACH, Shira ,  SAMEACH-GREENWALD, Shirley ,  DASSA, Liat ,  BEIMAN, Merav ,  MONTIA, Eve ,  LEVY, Ofer ,  NOVIK, Amit

IPC分类号： C07K16/28 ,  C07K14/705

CPC分类号： C07K16/28 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3038 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/577 ,  G01N2333/47

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against FAM26F antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of FAM26F, proteins and variants, and therapeutic usages thereof.

摘要翻译： 本发明涉及用于产生免疫和非免疫的治疗剂和疾病诊断的新靶标。 更具体地，本发明提供了针对FAM26F抗原的治疗性抗体，其在癌症中差异表达，以及诊断和治疗用途。 本发明还涉及FAM26F的细胞外结构域，蛋白质和变体及其治疗用途。

公开(公告)号：EP2373690B1

公开(公告)日：2015-02-11

申请号：EP09799402.4

申请日：2009-12-08

申请人： Compugen Ltd.

发明人： LEVINE, Zurit ,  ROSENBERG, Avi Yeshah ,  ROTMAN, Galit ,  TOPORIK, Amir ,  KINAR, Yaron ,  NEMZAR, Sergey ,  COHEN-DAYAG, Anat ,  WALACH, Shira ,  SAMEACH-GREENWALD, Shirley ,  DASSA, Liat ,  BEIMAN, Merav ,  MONTIA, Eve ,  LEVY, Ofer ,  NOVIK, Amit

IPC分类号： C07K16/28 ,  C07K14/705

CPC分类号： C07K16/28 ,  A61K38/00 ,  A61K39/39558 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K16/3015 ,  C07K16/3038 ,  C07K16/3053 ,  C07K16/3061 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/6886 ,  C12Q2600/136 ,  G01N33/57484 ,  G01N33/577 ,  G01N2333/47

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against FAM26F antigens, which are differentially expressed in cancer, and diagnostic and therapeutic usages. This invention further relates to extracellular domains of FAM26F, proteins and variants, and therapeutic usages thereof.

公开(公告)号：EP2245055A2

公开(公告)日：2010-11-03

申请号：EP09706816.7

申请日：2009-02-01

申请人： Compugen Ltd.

发明人： LEVIN, Zurit ,  ROSENBERG, Avi Yeshah ,  ROTMAN, Galit ,  TOPORIK, Amir ,  DASSA, Liat ,  BEIMAN, Merav ,  LEVY, Ofer ,  NEMZAR, Sergey ,  WALACH, Shira ,  SAMEACH-GREENWALD, Shirley ,  MONTIA, Eve ,  KINAR, Yaron ,  COHEN-DAYAG, Anat

IPC分类号： C07K14/47

CPC分类号： A61K39/3955 ,  C07K14/47 ,  C07K16/28 ,  C07K16/2887 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34

摘要： This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development.